Clarithromycin (TE-031) is a newly synthesized macrolide with high stability in acidic conditions. In the present study, the pharmacokinetics of [N-methyl-14C] 
[14C]clarithromycin in plasma and tissues were found to be significantly higher than those of [14C]erythromycin at the same oral dose of 20 mg/kg (body weight). Among the tissues, the peak level of [14C] Clarithromycin (TE-031) is a new macrolide antibiotic with a methoxy substituent for the hydroxy group at position 6 of the erythromycin A lactone ring. It was previously reported that the in vitro antibacterial activity of clarithromycin was almost comparable to that of erythromycin against various bacterial species (S. Morimoto, T. Adachi, Y. Takahashi, T. Asaka, M. Kashimura, Y. Watanabe, S. Omura, and K. Sota, Program Abstr. 26th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 409, 1986) . However, in mouse protection tests when the agent was administered orally, clarithromycin was 2 to 10 times more effective than erythromycin against various bacteria (R. Swanson, E. Gade, N. Shipkowitz, R. Bower, K. Jarvis, M. Mitten, N. Ramer, and P. B. Fernandes, 26th ICAAC, abstr. no. 411, 1986) .
It is known that erythromycin in acidic media rapidly loses its biological activity because of extensive acid-catalyzed transformation (4, 8) . On the contrary, it was found that clarithromycin is highly stable under acidic conditions, probably implying a high stability in gastric acid upon oral administration (10; Morimoto et al., 26th ICAAC). These facts suggest that the superior protective effects of clarithromycin in experimental animal infections may be the result of improved bioavailability.
Many investigators have reported on the metabolic fate of erythromycin (1, 2, (5) (6) (7) 11 Fig. 1 .
Experimental animals. The animals used were male Wistar rats weighing about 160 g and obtained from Shizuoka Laboratory Animal Center. They were fasted overnight before use, except when given a dose intravenously. The rats were given single oral doses of 5 or 20 mg of ['4C]clarithromycin per kg of body weight, 20 mg of ['4C]erythromycin per kg as a suspension in 5% gum arabic, or an intravenous dose of 5 mg of both labeled compounds per kg as a solution of saline with equimolar HCl to dissolve each compound.
Collection of biological samples. In the distribution study, whole blood was withdrawn from the inferior aorta into heparinized containers at preindicated times after dosing. Plasma was separated by centrifugation at 2,000 x g, 4°C, for 10 min. After blood collection, the liver, kidney, lung, heart, and spleen were excised from each animal. All tissues were weighed, and a 20% homogenate of each tissue was prepared with 1/15 M phosphate buffer at pH 7.2. In the excretion study, the rats given a dose were individually housed in metabolic cages which permitted separate collection of urine, feces, and pulmonary CO2. Bile was collected from rats kept in Bollman restricted cages via a common bile duct cannula. Each sample was collected for 24 h after dosing.
Radioassay erythromycin.
urine and bile was determined directly in Aquasol-IT (New England Nuclear). Pulmonary CO2 was trapped in a mixture of monoethanolamine and methanol (3:2, vol/vol). An additional 2 ml of methanol was added to the mixture (0.5 ml) before determination of radioactivity in the scintillator. Plasma and homogenates of both tissues and feces were dissolved with Soluen-350 (Packard) and decolorized by the addition of hydrogen peroxide prior to determination of radioactivity.
Bioassay. Microbiological assays of plasma, tissues, and excreta were performed by the paper disk (8-mm diameter; Toyo Seisakusho) method, with Micrococcus luteus ATCC 9341 as the test organism. Plasma, bile, and homogenates of both tissues and feces adjusted to pH 9 with 10% NaHCO3 were extracted with ethyl acetate and concentrated to a small volume before assay. Bioactive concentrations in the samples were calculated from the standard curve by conventional methods. The 95% confidence limit for the assay was better than ±17.2%. Under these extraction and bioassay conditions, the average recoveries of clarithromycin and erythromycin in spiked tissues were 102% ± 15% (standard error of the mean) and 110% ± 13%, respectively. The lower limit of sensitivity of the assay was 0.1 p,g/ml for both 5 and 20 mg/kg, the peak levels in plasma of radioactivity achieved at 2 h were 2.6 and 5.3 ,ug eq/ml, respectively. The levels declined gradually with time. In the tissues, concentrations of radioactivity for both doses were generally higher than those in the plasma. The highest concentration was found in the liver for the dose of 5 mg/kg. Concentrations were moderate in the lung, kidney, and spleen. On the other hand, at a dose of 20 mg/kg, tissue/ plasma concentration ratios were relatively higher than those at the 5-mg/kg dose. The highest concentration was found in the lung; it was 13 times that of plasma 2 h after administration, followed in descending order by concentrations in the liver, spleen, kidney, and heart.
When ['4C]erythromycin was administered at a dose of 20 mg/kg, the levels of radioactivity in plasma were significantly lower than those of [14C]clarithromycin, with a peak level of 2.8 ,ug eq/ml. Among the tissues, the highest concentration was found in the liver; however, the concentrations in all other tissues were considerably lower than those of ['4C]clarithromycin; the lung peak level was just 1/15 of that found for [14C]clarithromycin.
(ii) Bioactivity. Concentrations of bioactivity in plasma and tissue after ['4C]clarithromycin dosing were generally lower than those of radioactivity. Among the tissues, the bioactivity/radioactivity ratio was relatively high in the lung, heart, and spleen for doses of both 5 and 20 mg/kg, whereas it was very low in the plasma and liver. Concentrations in all tissues increased over the dose range; levels in plasma 2 h after administration of 5 and 20 mg/kg were <0.1 and 1.2 ,ug eq/ml, respectively. At the dose of 20 mg/kg, the highest concentration was observed in the lung at 2 h; it was 36 times that of plasma, followed in descending order by concentrations in the spleen, kidney, liver, and heart. As for [ ClarithrOmYCin ( It has been reported that levels of various macrolide antibiotics in tissue are much higher than levels in plasma of both radio-and bioactivities (3, 12, 14, 17 (3, 13, 17) . These characteristics may mean a relatively high tissue affinity and easy metabolism for macrolides, including erythromycin. However, this is not the case for clarithromycin. The levels of [14C]clarithromycin derived from radio-and bioassay were found to be roughly comparable in the lung, heart, and spleen; and they were rather long lasting. Therefore, it is suggested that, in addition to having high stability for gastric acid, clarithromycin may be less easily metabolized in the body. These data suggest that most radioactivity found in the feces probably originated in the bile for both compounds, and biliary transport was indicated to be a more important excretion route for erythromycin than for clarithromycin.
Regarding the different excretion patterns of ['4C] clarithromycin at doses of 5 and 20 mg/kg, it is noteworthy that urinary excretion of radioactivity increased as the dose increased, while fecal and biliary excretions decreased. When macrolide antibiotic SF-837 was administered intravenously to rats, it was reported that the biliary-to-urinaryexcretion ratio decreased with increasing dosage, suggesting a metabolic saturation in the liver (15, 16) . These results coincide with the above-described results with ['4CJclarith-romycin. Similarly, there may be metabolic saturation at higher doses. In addition, Mashimo et al. (9) examined the metabolic features of the macrolide josamycin in dogs and revealed some important points. Orally administered josamycin is predominantly excreted into the bile, and only after the biliary excretion is saturated does it flow into the hepatic veins. All josamycin flowing from the liver is carried through the right heart and pulmonary artery to the lung.
From this point of view, the observations of the present distribution study, i.e., the increasing tissue/plasma ratios of radioactivity at higher doses of ['4C]clarithromycin and increasing tissue concentrations of bioactivity over the dose range, might be the result of the saturation of the first-pass metabolism of clarithromycin in the liver and also of its high tissue affinity, especially to the lung. In conclusion, taking into consideration all the results described above, clarithromycin has pharmacokinetic properties superior to those of erythromycin owing to its higher tissue affinity, especially to the lung, and favorable urinary excretion. This may provide clinical usefulness not only for respiratory tract infections but for urinary tract infections, for which most previously known macrolides have failed to have significant impact.
